Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
|Osteoporosis||Procedure: bone densitometry (DEXA) Drug: alendronate or risedronate||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
|Official Title:||Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|
- the number of patients who get a BMD and the number who are started on active osteoporosis therapy
|Study Start Date:||January 2002|
|Estimated Study Completion Date:||April 2006|
All hip fracture patients in the Edmonton area will be screened for eligibility (mini-mental status >20, not on active osteoporosis pharmacologic therapy). All patients will have informed consent obtained. Patients will be randomized to 2 groups:
- Group 1: Active intervention. The fracture manager will arrange for bone densitometry (DEXA) to be done 3-6 months after the fracture. If the patient meets standard criteria for osteoporosis, therapy with a bisphosphonate (alendronate or risedronate) will be instituted by the study physicians.
- Group 2: Usual care. Patients will receive basic information about calcium and vitamin D and osteoporosis and told to follow up with their family doctor. At 6 months, patients will be contacted to determine if they have had a BMD done or started on active (drug) osteoporosis therapy. If not, the fracture manager will arrange the BMD and if appropriate therapy will be started by the study physicians.
All patients will be followed for 1 year. The primary endpoints are the number of patients who get a BMD and the number who are started on active osteoporosis therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00136058
|University of Alberta|
|Edmonton, Alberta, Canada, T6G2S2|
|Principal Investigator:||Donald W Morrish, MD, PhD||University of Alberta|